SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (4013)12/8/2015 12:51:45 PM
From: mulanoon2007  Read Replies (1) of 4474
 
In justification of the phase III and dose-range finding trials earlier in the year Dr Clackson mentioned the attraction of early activity/efficacy read-out by biomarkers. i.e. landmark time-points are well described for NIL (and other 2GTKIs) with the 3-month time-point being predictive of later land-mark time-points (and indeed long-term PFS). An update of biomarkers at the three-month landmark time-point is not inconceivable, is it? Early termination for futility would reduce the cost of trial failure but beat up PPS. My prejudice is that ARIA know enough to have confidence in safety and comparative efficacy. But I think Biomaven's point on whether this is the best use of cash is good.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News